As of 2024-12-13, the EV/EBITDA ratio of Ionis Pharmaceuticals Inc (IONS) is -10.94. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IONS's latest enterprise value is 4,639.16 mil USD. IONS's TTM EBITDA according to its financial statements is -424.12 mil USD. Dividing these 2 quantities gives us the above IONS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.5x - 11.8x | 11.2x |
| Forward P/E multiples | 11.6x - 16.9x | 14.2x |
| Fair Price | (23.53) - (24.07) | (26.48) |
| Upside | -163.6% - -165.0% | -171.6% |
| Date | EV/EBITDA |
| 2024-11-27 | -10.52 |
| 2024-11-26 | -10.33 |
| 2024-11-25 | -10.36 |
| 2024-11-22 | -9.82 |
| 2024-11-21 | -9.80 |
| 2024-11-20 | -10.34 |
| 2024-11-19 | -9.72 |
| 2024-11-18 | -9.72 |
| 2024-11-15 | -9.94 |
| 2024-11-14 | -11.02 |
| 2024-11-13 | -11.22 |
| 2024-11-12 | -11.22 |
| 2024-11-11 | -11.63 |
| 2024-11-08 | -11.75 |
| 2024-11-07 | -11.48 |
| 2024-11-06 | -11.69 |
| 2024-11-05 | -11.60 |
| 2024-11-04 | -11.47 |
| 2024-11-01 | -11.59 |
| 2024-10-31 | -11.45 |
| 2024-10-30 | -11.78 |
| 2024-10-29 | -11.94 |
| 2024-10-28 | -12.19 |
| 2024-10-25 | -11.75 |
| 2024-10-24 | -11.59 |
| 2024-10-23 | -11.46 |
| 2024-10-22 | -11.56 |
| 2024-10-21 | -11.68 |
| 2024-10-18 | -11.93 |
| 2024-10-17 | -11.49 |
| 2024-10-16 | -11.74 |
| 2024-10-15 | -11.25 |
| 2024-10-14 | -11.54 |
| 2024-10-11 | -11.47 |
| 2024-10-10 | -11.29 |
| 2024-10-09 | -11.33 |
| 2024-10-08 | -11.23 |
| 2024-10-07 | -11.25 |
| 2024-10-04 | -11.27 |
| 2024-10-03 | -11.24 |
| 2024-10-02 | -11.82 |
| 2024-10-01 | -11.71 |
| 2024-09-30 | -12.07 |
| 2024-09-27 | -12.37 |
| 2024-09-26 | -12.46 |
| 2024-09-25 | -12.42 |
| 2024-09-24 | -12.42 |
| 2024-09-23 | -12.73 |
| 2024-09-20 | -13.08 |
| 2024-09-19 | -13.07 |